Literature DB >> 15336702

Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.

F Chen1, K Knecht, C Leu, S J Rutledge, A Scafonas, C Gambone, R Vogel, H Zhang, V Kasparcova, C Bai, S Harada, A Schmidt, A Reszka, L Freedman.   

Abstract

Androgens play important endocrine roles in development and physiology. Here, we characterize activities of two "Andro" prohormones, androstenedione (A-dione) and 4-androsten-3beta,17beta-diol (A-diol) in MDA-MB-453 (MDA) and LNCaP cells. A-dione and A-diol, like cyproterone acetate, were partial agonists of transfected mouse mammary tumor virus (MMTV) and endogenous prostate-specific antigen (PSA) promoters. Different from bicalutamide but similar to CPA, both are inducers of LNCaP cell proliferation with only mild suppression of 5alpha-dihydrotestosterone (DHT)-enhanced cell growth. Like bicalutamide and cyproterone acetate, A-dione and A-diol significantly antagonized DHT/R1881-induced PSA expression by up to 30% in LNCaP cells. Meanwhile, in MDA cells, EC(50)s for the MMTV promoter were between 10 and 100nM. Co-factor studies showed GRIP1 as most active for endogenous androgen receptor (AR), increasing MMTV transcription by up to five-fold, without substantially altering EC(50)s of DHT, A-dione or A-diol. Consistent with their transcriptional activities, A-dione and A-diol bound full-length endogenous AR from MDA or LNCaP cells with affinities of 30-70nM, although binding to expressed ligand-binding domain (LBD) was >20-fold weaker. In contrast, DHT, R1881, and bicalutamide bound similarly to LBD or aporeceptor. Together, these data suggest that A-dione and A-diol are ligands for AR with partial agonist/antagonist activities in cell-based transcription assays. Binding affinities for both are most accurately assessed by AR aporeceptor complex. In addition to being testosterone precursors in vivo, either may impart its own transcriptional regulation of AR.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15336702     DOI: 10.1016/j.jsbmb.2004.04.009

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  16 in total

1.  Discovery and biological characterization of a novel series of androgen receptor modulators.

Authors:  C Zhou; G Wu; Y Feng; Q Li; H Su; D E Mais; Y Zhu; N Li; Y Deng; D Yang; M-W Wang
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

2.  Metabolomic patterns and alcohol consumption in African Americans in the Atherosclerosis Risk in Communities Study.

Authors:  Yan Zheng; Bing Yu; Danny Alexander; Lyn M Steffen; Jennifer A Nettleton; Eric Boerwinkle
Journal:  Am J Clin Nutr       Date:  2014-04-23       Impact factor: 7.045

3.  Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology.

Authors:  Azriel Schmidt; Donald B Kimmel; Chang Bai; Angela Scafonas; Sujane Rutledge; Robert L Vogel; Sheila McElwee-Witmer; Fang Chen; Pascale V Nantermet; Viera Kasparcova; Chih-Tai Leu; Hai-Zhuan Zhang; Mark E Duggan; Michael A Gentile; Paul Hodor; Brenda Pennypacker; Patricia Masarachia; Evan E Opas; Sharon A Adamski; Tara E Cusick; Jiabing Wang; Helen J Mitchell; Yuntae Kim; Thomayant Prueksaritanont; James J Perkins; Robert S Meissner; George D Hartman; Leonard P Freedman; Shun-ichi Harada; William J Ray
Journal:  J Biol Chem       Date:  2010-03-31       Impact factor: 5.157

4.  Ligand binding to the androgen receptor induces conformational changes that regulate phosphatase interactions.

Authors:  Chun-Song Yang; Hong-Wu Xin; Joshua B Kelley; Adam Spencer; David L Brautigan; Bryce M Paschal
Journal:  Mol Cell Biol       Date:  2007-02-26       Impact factor: 4.272

5.  Human metabolome associates with dietary intake habits among African Americans in the atherosclerosis risk in communities study.

Authors:  Yan Zheng; Bing Yu; Danny Alexander; Lyn M Steffen; Eric Boerwinkle
Journal:  Am J Epidemiol       Date:  2014-05-06       Impact factor: 4.897

Review 6.  Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery.

Authors:  Gonda Konings; Linda Brentjens; Bert Delvoux; Tero Linnanen; Karlijn Cornel; Pasi Koskimies; Marlies Bongers; Roy Kruitwagen; Sofia Xanthoulea; Andrea Romano
Journal:  Front Pharmacol       Date:  2018-09-19       Impact factor: 5.810

7.  Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands.

Authors:  Azriel Schmidt; Shun-Ichi Harada; Donald B Kimmel; Chang Bai; Fang Chen; Su Jane Rutledge; Robert L Vogel; Angela Scafonas; Michael A Gentile; Pascale V Nantermet; Sheila McElwee-Witmer; Brenda Pennypacker; Patricia Masarachia; Soumya P Sahoo; Yuntae Kim; Robert S Meissner; George D Hartman; Mark E Duggan; Gideon A Rodan; Dwight A Towler; William J Ray
Journal:  J Biol Chem       Date:  2009-10-21       Impact factor: 5.157

Review 8.  Hormone-mediated maternal effects in birds: mechanisms matter but what do we know of them?

Authors:  Ton G G Groothuis; Hubert Schwabl
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-05-12       Impact factor: 6.237

9.  Prostaglandin 15d-PGJ(2) inhibits androgen receptor signaling in prostate cancer cells.

Authors:  Sanna Kaikkonen; Ville Paakinaho; Päivi Sutinen; Anna-Liisa Levonen; Jorma J Palvimo
Journal:  Mol Endocrinol       Date:  2012-11-28

10.  Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours.

Authors:  D Alwyn Dart; Bradley Spencer-Dene; Simon C Gamble; Jonathan Waxman; Charlotte L Bevan
Journal:  Endocr Relat Cancer       Date:  2009-07-27       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.